Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

38.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 38.36
Bid (Size) 21.00 (1)
Ask (Size) 40.00 (1)
Prev. Close 38.36
Today's Range 38.36 - 38.36
52wk Range 33.49 - 73.80
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-37.39%
-37.39%
1 Month
+6.08%
+6.08%
3 Month
-9.74%
-9.74%
6 Month
-33.12%
-33.12%
1 Year
-9.19%
-9.19%

More News

Read More
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
Via InvestorPlace
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Via Benzinga
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
Via Benzinga
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
What Analysts Are Saying About Apellis Pharmaceuticals Stock
Via Benzinga
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
Via Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.